Travere therapeutics reports second quarter 2023 financial results

• received 417 new patient start forms for filspari™(sparsentan) in the second quarter 2023, reflecting continued strong demand from nephrologists and patients with iga nephropathy (igan)

TVTX Ratings Summary

TVTX Quant Ranking